SemperVirens Ventures

General partners Rob Carroll, Colin Tobias, and Allison Baum Gates make all investment decisions. The firm's ecosystem council of HR and benefits executives provides sourcing and diligence input, but does not have committee voting power. The partnership model keeps decision-making authority with the three GPs.

SemperVirens sources primarily through its employer ecosystem council, a curated group of CHROs, benefits leaders, and health plan administrators. These partners surface pain points from their own organizations and refer startups that have demonstrated traction with enterprise buyers. The firm supplements this with traditional venture networks, but the ecosystem council is the structural sourcing engine.

The firm is concentrated at pre-seed and seed stages. SemperVirens writes first-check investments and maintains reserves for follow-on through a dedicated opportunity fund. The fund does not lead growth rounds but participates in early-stage extensions for top-performing portfolio companies.

SemperVirens invests in workforce technology that spans digital health, financial wellness, insurtech, and AI applications for HR. The unifying theme is technology that serves employees through their employer relationship. The firm generally avoids consumer-direct health businesses without an employer distribution angle and stays away from direct-to-consumer models where the employer is not the primary channel.

The firm's ecosystem partners can pilot portfolio products with their own employee populations, providing real-world product feedback and an enterprise reference customer. The GPs also run programming that connects portfolio founders to benefits buyers at large self-insured employers. This distribution-access model is the firm's core argument for its relevance in competitive seed rounds.

SemperVirens operates as a traditional venture capital firm structured around committed fund vehicles. It is not a family office. The firm raises capital from institutional limited partners and strategic employer-partners through closed-end fund structures typical of early-stage venture firms.

The firm's public track record remains early-stage, consistent with a 2018 vintage. Specific realized exits have not been publicly disclosed. Many portfolio companies remain private, and the firm's returns are still maturing. Institutional allocators evaluating the firm typically weigh the employer-ecosystem distribution thesis alongside the yet-unproven fund-level track record.